CTOs on the Move

Xenon Pharmateuticals

www.xenon-pharma.com

 
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Xenon Pharmateuticals raised $63M on 09/17/2018
Xenon Pharmateuticals raised $30M on 12/02/2019
Xenon Pharmateuticals raised $115M on 03/10/2021

Similar Companies

Medical Practice Management Services

Medical Practice Management Services is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New London Hospital

New London Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. New London Hospital is based in New London, NH. You can find more information on New London Hospital at www.newlondonhospital.org

LVM Systems

LVM Systems is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lachance Center For Nursing

Lachance Center For Nursing is a Gardner, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.